Acumen Pharmaceuticals, Inc.
Records under this name other than the patents Acumen Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 8 of 8 · Back to Acumen Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,359 | Compositions and Methods for the Enhancement of Soluble Amyloid Beta Oligomer (ADDL) Uptake and Clearance Formerly held In force · High confidence | In force | High confidence | |
| US 8,507,206 | Monoclonal Antibodies That Target Pathological Assemblies of Amyloid B (ABETA) Formerly held In force · High confidence | In force | High confidence | |
| US 9,176,151 | Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers Formerly held In force · High confidence | In force | High confidence | |
| US 9,310,383 | Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers Formerly held In force · High confidence | In force | High confidence | |
| US 9,320,793 | Method for Treating a Disease Associated with Soluble, Oligomeric Species of Amyloid Beta 1-42 Formerly held In force · High confidence | In force | High confidence | |
| US 9,006,283 | Methods of modifying amyloid β oligomers using non-peptidic compounds Lapsed on the fee record Ended Apr 14, 2019 · USPTO record | Lapsed on the fee record | Ended Apr 14, 2019 | USPTO record |
| US 8,962,677 | Methods of restoring cognitive ability using non-peptidic compounds Lapsed on the fee record Ended Feb 24, 2019 · USPTO record | Lapsed on the fee record | Ended Feb 24, 2019 | USPTO record |
| US 6,218,506 | Amyloid .beta. protein (globular assembly and uses thereof) Formerly held Term ended Term ended Feb 5, 2017 · USPTO record | Term ended | Term ended Feb 5, 2017 | USPTO record |